Sin spam. Cancela en cualquier momento.
Análisis de Pureza HPLC
MK677
CAS: 159634-47-6
Estudiado para la elevación sostenida de GH con dosificación oral
MK677 es un péptido de investigación en la categoría de hormona de crecimiento / secretagogos de GH. MK-677 es un agonista del receptor de grelina (GHSR-1a), no peptídico y activo por vía oral, que imita la actividad liberadora de GH de la grelina. MiPeptidos ofrece MK677 en 1 tamaño con 99.1% de pureza verificada y documentación analítica completa.
- Elevación de GH las 24 horas
- Sueño más profundo y sueños vívidos
- Niveles juveniles de IGF-1 restaurados
- Respaldado por datos de ensayos de 2 años
Los estudios reportan un sueño drásticamente mejor y sueños vívidos dentro de los primeros días, junto con aumento del apetito. Entre las semanas 3-6, la investigación sugiere que el IGF-1 aumenta un 40-60% a niveles juveniles, la calidad de la piel mejora y la recuperación se acelera. Un ensayo clínico histórico de 2 años mostró beneficios sostenidos sin que el cuerpo se adapte y pierda efectividad.
$14.59/vial · Everything you need to start
Sin spam. Cancela en cualquier momento.
Análisis de Pureza HPLC
Sustained GH Optimization.
12-week protocol backed by 2-year clinical trial data for sustained IGF-1 elevation
MK-677 (Ibutamoren) is a non-peptide growth hormone secretagogue that mimics ghrelin signaling at the GHS receptor (GHSR-1a). It has a 24-hour duration of action, enabling once-daily dosing for sustained GH and IGF-1 elevation.
Resultados Publicados
Revisado por ParesResultados cuantificables de investigación clínica publicada.
Lo que Dicen los Expertos
4 MédicosProfesionales e investigadores líderes que han estudiado y prescrito este péptido.
Dr. Michael Thorner
Professor of Medicine, University of Virginia
Leading endocrinologist in GH secretagogue research. Principal investigator on the landmark MK-677 clinical trials. Published extensively on GH secretagogues.
MK-677 increased pulsatile GH secretion and IGF-1 to the level of healthy young adults in elderly subjects. The 24-hour duration makes it uniquely practical among GH secretagogues.
5 mg subcutaneous once daily (bedtime). Sustained IGF-1 elevation for 12+ months without tachyphylaxis. Monitor IGF-1 and fasting glucose.
Fuente: Nass et al. (2008) J Clin Endocrinol Metab; Murphy et al. (1998) JCEM
Dr. William Seeds
Founder, SSRP Institute
40+ years in cellular and molecular medicine. Author of 'Peptide Protocols: Volume 1'.
MK-677 is a GH secretagogue with long-term clinical data. Once-daily dosing and sustained IGF-1 elevation for months. It's one of the easiest GH optimization protocols that exists.
5 mg subcutaneous at bedtime. Start at lower dose for 2 weeks to assess tolerance, then titrate up. Bedtime dosing amplifies nocturnal GH pulse. Monitor appetite (ghrelin-mediated increase) and fasting glucose.
Fuente: Peptide Protocols: Volume 1 (ISBN: 978-0578624358)
Dr. Andrew Huberman
Professor of Neurobiology, Stanford University
Ph.D. in Neuroscience. Host of Huberman Lab.
MK-677 is remarkable because it's long-acting and has 2-year clinical trial data. The IGF-1 elevation is sustained without tachyphylaxis. The main concerns are appetite increase and potential insulin resistance with chronic use.
Bedtime dosing to align with nocturnal GH pulse. Start at lower dose and assess appetite and sleep effects. Monitor fasting glucose — MK-677 can impair glucose tolerance over time.
Fuente: Huberman Lab Podcast: Peptide Therapeutics Discussion (2024)
Dr. Ralf Nass
Associate Professor of Medicine, University of Virginia
Endocrinologist specializing in GH axis physiology. Co-investigator on the landmark 2-year MK-677 trial in elderly subjects.
Two years of daily MK-677 restored GH and IGF-1 to youthful levels in healthy older adults. The compound increased fat-free mass and was generally well tolerated over the full 2-year period.
5 mg subcutaneous daily dosing. In the 2-year trial, IGF-1 was elevated to the level of healthy young adults. Fat-free mass increased. Main adverse effect was transient appetite increase and fasting glucose elevation.
Fuente: Nass et al. (2008) Ann Intern Med; PMID: 18711153
Protocolo de Dosificación
3 FasesRégimen de dosificación paso a paso compilado de profesionales líderes e investigación clínica.
Start at lower dose to assess appetite stimulation and tolerance. Bedtime dosing amplifies nocturnal GH pulse and sleep quality. Appetite increase is expected (ghrelin pathway).
Standard dose. Once-daily subcutaneous administration. IGF-1 elevation sustained throughout dosing period. Monitor fasting glucose monthly.
2-year clinical trial data supports long-term use. No tachyphylaxis. Some practitioners use 5-on/2-off for maintenance. Quarterly IGF-1 and glucose monitoring.
Add 1 mL bacteriostatic water to 5 mg vial = 5 mg/mL. Reconstitute gently — do not shake. Use insulin syringe for precise measurement.
Clinical trial: continuous daily dosing for up to 2 years without tachyphylaxis. Some practitioners cycle 8–12 weeks on, 4 weeks off. Others run continuously with monitoring.
Lyophilized: store at -20°C or 2–8°C away from light. Reconstituted: 2–8°C, use within 28 days. MK-677 is a non-peptide small molecule — more stable than most peptide compounds.
Subcutaneous injection once daily before bed. Bedtime dosing is preferred to align with the natural nocturnal GH surge and to minimize daytime appetite effects. Rotate injection sites.
Cronología de Recuperación
Basado en observaciones de investigación publicada. Los resultados individuales varían. Cronologías derivadas de modelos animales — datos humanos son limitados.
GH Pulsatility Enhancement & Sleep Improvement
- GH pulsatility increased within 24 hours of first dose
- Improved sleep quality and depth — often the first noticeable benefit
- Increased appetite within 1–3 days (ghrelin-mediated)
- Vivid dreams common (marker of enhanced deep sleep)
- Mild water retention and bloating (resolves by week 2–3)
Base de investigación: Copinschi et al. (1997) Neuroendocrinology; Murphy et al. (1998) JCEM
IGF-1 Elevation & Body Composition Shifts
- IGF-1 elevated to youthful range (40–60% above baseline typical)
- Improved recovery from exercise and training
- Enhanced skin quality and hydration
- Appetite stabilizes as tolerance develops
- Subtle body composition changes — improved muscle fullness
Base de investigación: Nass et al. (2008) Ann Intern Med; Murphy et al. (1998)
Peak Benefits & Sustained Response
- IGF-1 levels maintained without tachyphylaxis
- Measurable increase in fat-free mass
- Bone mineral density improvement beginning
- Sustained sleep quality and recovery enhancement
- Fasting glucose may rise slightly — monitor closely
Base de investigación: Nass et al. (2008); MK-677 12-month trial data
Long-Term Maintenance
- 2-year clinical data confirms sustained IGF-1 elevation
- Fat-free mass gains maintained
- Bone density improvements measurable at 12+ months
- GH pulsatility remains enhanced — no desensitization
- Monitor glucose metabolism — some develop insulin resistance
Base de investigación: Nass et al. (2008) PMID: 18711153 — 2-year data
Mecanismo de Acción
4 vías biológicas distintas a través de las cuales opera este péptido.
GHSR-1a Agonism
MK-677 is a non-peptide small molecule that mimics ghrelin at the GHSR-1a receptor with a 24-hour duration of action, enabling once-daily dosing for sustained GH secretion.
- Non-peptide small molecule with 24-hour duration of action
- Activates GHSR-1a identically to endogenous ghrelin
- Single daily dose sufficient for sustained GH pulsatility enhancement
Nass et al. (2008) PMID: 18711153; Smith et al. (1997)
Sustained GH Pulsatility Enhancement
MK-677 increases the amplitude and frequency of GH pulses without disrupting the natural pulsatile pattern, restoring GH secretion to youthful levels in elderly subjects.
- Enhances both GH pulse amplitude and frequency
- Preserves somatostatin feedback — natural pulsatility maintained
- No tachyphylaxis over 2 years of continuous daily dosing
Nass et al. (2008) PMID: 18711153; Jacks et al. (1996) PMID: 8814349
Sleep Architecture Enhancement
MK-677 increases slow-wave sleep (Stage 3/4 NREM) by 50% and REM sleep by 20%, with GH secretion increasing in parallel — one of the few compounds with demonstrated sleep-architecture benefits.
- 50% increase in slow-wave sleep duration
- 20% increase in REM sleep duration
- GH secretion increases in parallel with sleep enhancement
Copinschi et al. (1997) PMID: 9394054
Appetite & Metabolic Regulation
As a ghrelin receptor agonist, MK-677 activates hypothalamic appetite circuits, increasing hunger and caloric intake — a significant effect that requires dietary awareness.
- Activates NPY/AgRP neurons in the hypothalamus
- Appetite increase most pronounced in first 2–4 weeks
- Tolerance to appetite effects develops partially with continued use
Svensson et al. (1998) PMID: 9435547
Investigación Publicada
6 estudios revisados por pares de PubMed. Haz clic en cualquier PMID para ver el estudio completo.
Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial
Nass R, Pezzoli SS, Oliveri MC, et al. — Annals of Internal Medicine (2008)
Hallazgo Clave: 2-year daily MK-677 (25 mg) in healthy elderly: restored GH pulsatility and IGF-1 to youthful levels, increased fat-free mass by 1.6 kg, and maintained bone mineral density. No tachyphylaxis over 2 years.
MK-677 stimulates GH secretion and improves body composition in obese subjects
Murphy MG, Plunkett LM, Gertz BJ, et al. — Journal of Clinical Endocrinology & Metabolism (1998)
Hallazgo Clave: MK-677 (25 mg/day) increased GH and IGF-1 and improved fat-free mass in obese subjects over 8 weeks. GH pulsatility was enhanced without suppression of normal feedback.
MK-677 enhances slow-wave sleep and GH secretion
Copinschi G, Leproult R, Van Onderbergen A, et al. — Neuroendocrinology (1997)
Hallazgo Clave: Single dose of MK-677 increased slow-wave sleep duration by 50% and REM sleep duration by 20% in young healthy subjects. GH secretion increased in parallel with sleep enhancement.
Oral administration of growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults
Murphy MG, Bach MA, Plotkin D, et al. — Journal of Bone and Mineral Research (1999)
Hallazgo Clave: MK-677 increased bone formation markers (osteocalcin) and bone turnover markers in elderly subjects, suggesting potential for preventing age-related bone loss.
Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677: changes in body composition and energy expenditure
Svensson J, Lonn L, Jansson JO, et al. — Journal of Clinical Endocrinology & Metabolism (1998)
Hallazgo Clave: MK-677 increased fat-free mass by 3 kg and basal metabolic rate significantly over 2 months in obese subjects. IGF-1 elevated 40–60% without suppression of endogenous GH pulsatility.
Chronic administration of MK-677 (Ibutamoren Mesylate) increases GH and IGF-1 in beagles without altering pulsatile GH secretion
Jacks T, Smith R, Judith F, et al. — Journal of Endocrinology (1996)
Hallazgo Clave: Chronic MK-677 administration maintained elevated GH and IGF-1 without altering normal GH pulsatile secretion pattern or causing desensitization over extended treatment periods.
Potencia tu Protocolo de Investigación
4 SinergiasLa investigación sugiere combinar MK677 con estos péptidos para mecanismos complementarios.
MK-677 provides sustained 24-hour GH support while CJC/Ipa provides amplified GH pulses — complementary mechanisms.
24-hour GH axis optimization — sustained MK-677 baseline plus amplified CJC/Ipa pulses for maximum IGF-1 output.
MK-677 increases appetite (ghrelin effect) which can counteract fat loss goals. Fragment 176-191 provides targeted lipolysis without appetite effects.
GH axis optimization (MK-677) plus targeted fat loss (Fragment 176-191) — the fragment counterbalances MK-677's appetite-stimulating tendency.
MK-677 (GHRP pathway) + Sermorelin (GHRH pathway) provides dual-pathway GH amplification.
Dual-pathway approach with the two best-characterized GH secretagogues — maximum GH axis support.
BPC-157 upregulates GH receptors while MK-677 sustains GH elevation — more signal meeting more receptors for enhanced tissue repair.
Sustained GH elevation with tissue-level receptor amplification — convenient and effective recovery kit.
Especificaciones
Cómo Funciona MK677
MK-677 is an orally active, non-peptidic ghrelin receptor (GHSR-1a) agonist that mimics the GH-releasing activity of ghrelin. It stimulates pituitary GH release by binding to GHSR-1a, increasing GH pulse amplitude without altering pulse frequency. It also increases IGF-1 levels, promotes nitrogen retention, and stimulates appetite. Unlike peptide GH secretagogues, it is orally bioavailable and has a long duration of action, maintaining elevated GH and IGF-1 levels with once-daily dosing.
Aplicaciones de Investigación
Precios
| Tamaño | Por Vial | Paquete de 10 |
|---|---|---|
5mg | $50.00 | $425.00 |
Precios de paquete de 10 mostrados. Descuentos por volumen para 50+ viales — contáctenos.
Certificado de Análisis
Este COA es una muestra representativa. Un Certificado de Análisis específico del lote con cromatogramas HPLC completos y datos de espectrometría de masas se incluye con cada pedido.
Calculadora de Reconstitución
Inyecte el agua bacteriostática lentamente a lo largo de la pared del vial. Agite suavemente hasta disolver — nunca sacuda. Almacene la solución reconstituida a 2-8°C y use dentro de 30 días.
Reseñas de Clientes
Preguntas Frecuentes
Seguridad y Advertencias
Not FDA-approved — investigational compound
MK-677 (Ibutamoren) reached Phase II clinical trials but was not brought to market. It is not an approved pharmaceutical. All information is for research and educational purposes.
Insulin resistance and glucose dysregulation with chronic use
The 2-year trial showed increased fasting glucose and HbA1c. MK-677 impairs insulin sensitivity in some individuals, particularly with long-term use. Monitor fasting glucose monthly.
Contraindicated with active cancer
Sustained IGF-1 elevation (24+ hours per dose) increases proliferative risk. Contraindicated with active malignancy, history of cancer, or unmonitored elevated IGF-1.
Solo para Fines de Investigación y Educación. No es consejo médico. No para consumo humano. Consulte a un médico autorizado antes de tomar cualquier decisión relacionada con la salud.
Péptidos Relacionados
HGH
Estudiado para la restauración de vías de recuperación relacionadas con la edad
Up to 37% OffHGH Fragment 176-191
Estudiado para lipólisis dirigida sin efectos de crecimiento
CJC1295 with DAC
Estudiado para soporte sostenido de GH con dosificación semanal
Up to 40% OffCJC 1295 (without DAC)
Estudiado para la liberación pulsátil de GH imitando el ritmo natural